Found: 165
Select item for more details and to access through your institution.
An open‐label, first‐in‐human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma.
- Published in:
- European Journal of Haematology, 2024, v. 113, n. 5, p. 593, doi. 10.1111/ejh.14270
- By:
- Publication type:
- Article
XBB.1.5 neutralizing antibodies upon bivalent COVID‐19 vaccination are similar to XBB but lower than BQ.1.1.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 5, p. E123, doi. 10.1002/ajh.26887
- By:
- Publication type:
- Article
Belantamab mafodotin induces immunogenic cell death within 24 h post‐administration in newly diagnosed multiple myeloma patients.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 3, p. E65, doi. 10.1002/ajh.26823
- By:
- Publication type:
- Article
Distinct neutralization profile of spike variants by antibodies induced upon SARS‐CoV‐2 infection or vaccination.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 1, p. E3, doi. 10.1002/ajh.26380
- By:
- Publication type:
- Article
Lenalidomide-associated pneumonitis in patients with plasma cell dyscrasias.
- Published in:
- American Journal of Hematology, 2011, v. 86, n. 10, p. 882, doi. 10.1002/ajh.22135
- By:
- Publication type:
- Article
Exercise-Induced Changes in Tumor Growth via Tumor Immunity.
- Published in:
- Sports (2075-4663), 2021, v. 9, n. 4, p. 46, doi. 10.3390/sports9040046
- By:
- Publication type:
- Article
Germline and somatic variants in ovarian carcinoma: A next-generation sequencing (NGS) analysis.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.1030786
- By:
- Publication type:
- Article
The Prognostic Role of BRD4 Expression in High-Grade Serous Ovarian Cancer.
- Published in:
- Cancers, 2024, v. 16, n. 11, p. 1962, doi. 10.3390/cancers16111962
- By:
- Publication type:
- Article
EPH/Ephrin Signaling in Normal Hematopoiesis and Hematologic Malignancies: Deciphering Their Intricate Role and Unraveling Possible New Therapeutic Targets.
- Published in:
- Cancers, 2023, v. 15, n. 15, p. 3963, doi. 10.3390/cancers15153963
- By:
- Publication type:
- Article
Optimal Time Interval between Neoadjuvant Platinum-Based Chemotherapy and Interval Debulking Surgery in High-Grade Serous Ovarian Cancer.
- Published in:
- Cancers, 2023, v. 15, n. 13, p. 3519, doi. 10.3390/cancers15133519
- By:
- Publication type:
- Article
Monoclonal Gammopathy of Thrombotic Significance.
- Published in:
- Cancers, 2023, v. 15, n. 2, p. 480, doi. 10.3390/cancers15020480
- By:
- Publication type:
- Article
Approach to Contemporary Risk Assessment, Prevention and Management of Thrombotic Complications in Multiple Myeloma.
- Published in:
- Cancers, 2022, v. 14, n. 24, p. 6216, doi. 10.3390/cancers14246216
- By:
- Publication type:
- Article
Low Spike Antibody Levels and Impaired BA.4/5 Neutralization in Patients with Multiple Myeloma or Waldenstrom's Macroglobulinemia after BNT162b2 Booster Vaccination.
- Published in:
- Cancers, 2022, v. 14, n. 23, p. 5816, doi. 10.3390/cancers14235816
- By:
- Publication type:
- Article
SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint Inhibition.
- Published in:
- Cancers, 2022, v. 14, n. 11, p. 2796, doi. 10.3390/cancers14112796
- By:
- Publication type:
- Article
Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study "REBUILD".
- Published in:
- Cancers, 2022, v. 14, n. 11, p. 2768, doi. 10.3390/cancers14112768
- By:
- Publication type:
- Article
Physical Exercise Restrains Cancer Progression through Muscle-Derived Factors.
- Published in:
- Cancers, 2022, v. 14, n. 8, p. 1892, doi. 10.3390/cancers14081892
- By:
- Publication type:
- Article
MicroRNAs as Potential Predictors of Response to CDK4/6 Inhibitor Treatment.
- Published in:
- Cancers, 2021, v. 13, n. 16, p. 4114, doi. 10.3390/cancers13164114
- By:
- Publication type:
- Article
Aberrant Plasma Cell Contamination of Peripheral Blood Stem Cell Autografts, Assessed by Next-Generation Flow Cytometry, Is a Negative Predictor for Deep Response Post Autologous Transplantation in Multiple Myeloma; A Prospective Study in 199 Patients.
- Published in:
- Cancers, 2021, v. 13, n. 16, p. 4047, doi. 10.3390/cancers13164047
- By:
- Publication type:
- Article
A Molecular Signature of Circulating MicroRNA Can Predict Osteolytic Bone Disease in Multiple Myeloma.
- Published in:
- Cancers, 2021, v. 13, n. 15, p. 3877, doi. 10.3390/cancers13153877
- By:
- Publication type:
- Article
Continuing Cancer Therapy through the Pandemic While Protecting Our Patients: Results of the Implementation of Preventive Strategies in a Referral Oncology Unit.
- Published in:
- Cancers, 2021, v. 13, n. 4, p. 763, doi. 10.3390/cancers13040763
- By:
- Publication type:
- Article
Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review.
- Published in:
- Cancers, 2021, v. 13, n. 3, p. 465, doi. 10.3390/cancers13030465
- By:
- Publication type:
- Article
Long-Term Neurodevelopmental Outcome of Children after in Utero Exposure to Chemotherapy.
- Published in:
- Cancers, 2020, v. 12, n. 12, p. 3623, doi. 10.3390/cancers12123623
- By:
- Publication type:
- Article
Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma.
- Published in:
- Cancers, 2020, v. 12, n. 11, p. 3245, doi. 10.3390/cancers12113245
- By:
- Publication type:
- Article
Antitumor Reactive T-Cell Responses Are Enhanced In Vivo by DAMP Prothymosin Alpha and Its C-Terminal Decapeptide.
- Published in:
- Cancers, 2019, v. 11, n. 11, p. 1764, doi. 10.3390/cancers11111764
- By:
- Publication type:
- Article
Treatment of early uterine sarcomas: disentangling adjuvant modalities.
- Published in:
- World Journal of Surgical Oncology, 2009, v. 7, p. 1, doi. 10.1186/1477-7819-7-38
- By:
- Publication type:
- Article
The role of CXC-chemokine receptor CXCR2 and suppressor of cytokine signaling-3 (SOCS-3) in renal cell carcinoma.
- Published in:
- BMC Cancer, 2014, v. 14, p. 1, doi. 10.1186/1471-2407-14-149
- By:
- Publication type:
- Article
The role of CXC-chemokine receptor CXCR2 and suppressor of cytokine signaling-3 (SOCS-3) in renal cell carcinoma.
- Published in:
- BMC Cancer, 2014, v. 14, n. 1, p. 1, doi. 10.1186/1471-2407-14-149
- By:
- Publication type:
- Article
The role of CXC-chemokine receptor CXCR2 and suppressor of cytokine signaling-3 (SOCS-3) in renal cell carcinoma.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Improved Survival Trends in Platinum-Resistant Patients with Advanced Ovarian, Fallopian or Peritoneal Cancer Treated with First-Line Paclitaxel/Platinum Chemotherapy: The Impact of Novel Agents.
- Published in:
- Oncology, 2013, v. 84, n. 3, p. 158, doi. 10.1159/000341366
- By:
- Publication type:
- Article
Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation.
- Published in:
- Oncologist, 2017, v. 22, n. 6, p. 667, doi. 10.1634/theoncologist.2016-0435
- By:
- Publication type:
- Article
Ectopic Cushing syndrome in metastatic castration‑resistant prostate cancer: A case report and review of literature.
- Published in:
- Oncology Letters, 2024, v. 28, n. 3, p. N.PAG, doi. 10.3892/ol.2024.14550
- By:
- Publication type:
- Article
Intravenous rituximab and oral cyclophosphamide for the treatment of cancer‑associated retinopathy in a patient with epithelial ovarian cancer: A case report.
- Published in:
- Oncology Letters, 2023, v. 26, n. 1, p. N.PAG, doi. 10.3892/ol.2023.13894
- By:
- Publication type:
- Article
Efficacy and immune modulation associated with the addition of IMiDs to Daratumumab backbone in multiple myeloma patients refractory to both drug classes: resetting synergistic activity.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-00988-x
- By:
- Publication type:
- Article
Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00797-8
- By:
- Publication type:
- Article
Clinical and biological implications of Hippo pathway dysregulation in sarcomas.
- Published in:
- Forum of Clinical Oncology, 2018, v. 9, n. 1, p. 11, doi. 10.2478/fco-2018-0002
- By:
- Publication type:
- Article
Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON Studies.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 9, p. 687, doi. 10.1016/j.clml.2023.05.004
- By:
- Publication type:
- Article
Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. 460, doi. 10.1016/j.clml.2022.01.011
- By:
- Publication type:
- Article
P-224: Pomalidomide, bortezomib, and dexamethasone after 1 prior line of therapy in relapsed or refractory multiple myeloma (RRMM): A safety subanalysis of the phase 3 OPTIMISMM trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S163, doi. 10.1016/S2152-2650(21)02351-X
- By:
- Publication type:
- Article
P-209: High response rates with IMiD retreatment post anti-CD38 exposure in patients with Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S154, doi. 10.1016/S2152-2650(21)02336-3
- By:
- Publication type:
- Article
P-206: SELECT Trial in Progress: an open-label, phase 2 study of Carfilzomib, Pomalidomide, and Dexamethasone in patients with first or second relapse of Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S152, doi. 10.1016/S2152-2650(21)02333-8
- By:
- Publication type:
- Article
P-204: Carfilzomib, Dexamethasone, and Daratumumab (KdD) vs Kd: subgroup analysis of the CANDOR study by prior autologous stem cell transplantation, Lenalidomide exposure, or Lenalidomide refractory disease.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S150, doi. 10.1016/S2152-2650(21)02331-4
- By:
- Publication type:
- Article
P-203: EXCALIBER: a phase 3 study comparing iberdomide, daratumumab, and dexamethasone (IberDd) with daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S150, doi. 10.1016/S2152-2650(21)02330-2
- By:
- Publication type:
- Article
P-193: Elotuzumab plus pomalidomide/dexamethasone for relapsed/refractory multiple myeloma: final overall survival from the phase 2 ELOQUENT-3 trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S143, doi. 10.1016/S2152-2650(21)02320-X
- By:
- Publication type:
- Article
P-191: Comparison of efficacy outcomes for Carfilzomib plus Dexamethasone and Daratumumab (KdD) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) and D-Pd in relapsed or refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S142, doi. 10.1016/S2152-2650(21)02318-1
- By:
- Publication type:
- Article
P-127: Patients with Multiple Myeloma on treatment with Anti-CD38 or Anti-BCMA agents have a suboptimal humoral response following COVID-19 vaccination.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S104, doi. 10.1016/S2152-2650(21)02254-0
- By:
- Publication type:
- Article
P-059: miRNA profiling of CD138+ plasma cells identifies miR-181a-5p overexpression as independent predictor of short-term progression and poor treatment outcome in multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S71, doi. 10.1016/S2152-2650(21)02193-5
- By:
- Publication type:
- Article
OAB-050: OCEAN (OP-103): a Phase 3, randomized, global, head-to-head comparison study of Melflufen and Dexamethasone (Dex) versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S32, doi. 10.1016/S2152-2650(21)02124-8
- By:
- Publication type:
- Article
OAB-038: Graded cardiac response criteria for AL amyloidosis: the impact of depth of cardiac response on survival.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S24, doi. 10.1016/S2152-2650(21)02112-1
- By:
- Publication type:
- Article
OAB-036: Graded renal response criteria and revised renal progression criteria for light chain (AL) amyloidosis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S23, doi. 10.1016/S2152-2650(21)02110-8
- By:
- Publication type:
- Article